Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTBK1 | Q5TCY1 | 3/20 | 0.59 |
| ▸ | TTBK2 | Q6IQ55 | 3/20 | 0.59 |
| ▸ | AURKA | O14965 | 3/20 | 0.56 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | DHODH | Q02127 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.46 |
| ▸ | EGFR | P00533 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5569470 | 0.85 | EGFR (0.58) | TTBK1TTBK2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL5568284 | 0.83 | KDM4E (0.53) | AURKARPS6KB1RAB9AMAPTNPC1 | |
| SCHEMBL5564469 | 0.82 | ABCG2 (0.55) | AURKARPS6KB1RAB9AMAPTNPC1 | |
| SCHEMBL5569158 | 0.80 | ABCG2 (0.69) | TTBK1TTBK2RAB9AMAPTNPC1 | |
| SCHEMBL5564499 | 0.80 | KDR (0.65) | TTBK1TTBK2RAB9AMAPTNPC1 | |
| Hydrochloric Acid SCHEMBL8809726 | 0.79 | ABCG2 (0.68) | TTBK1TTBK2RAB9AMAPTNPC1 | |
| SCHEMBL5569113 | 0.79 | EGFR (0.53) | TTBK1TTBK2AURKARPS6KB1RAB9A | |
| SCHEMBL5568069 | 0.79 | JAK2 (0.56) | TTBK1TTBK2AURKARPS6KB1RAB9A | |
| SCHEMBL5569346 | 0.79 | CCNT1 (0.50) | AURKARPS6KB1RAB9AMAPTNPC1 | |
| SCHEMBL5570053 | 0.79 | HPGD (0.52) | TTBK1TTBK2RAB9AMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | claimed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | claimed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | claimed |
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | GPC BIOTECH AG (DE) | 2007-05-31 | — | — | US | disclosed |
| EP-1673346-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC Biotech AG (DE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005040125-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF HERPESVIRAL INFECTIONS | GPC BIOTECH AG (DE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123537-A1 | Quinazoline derivatives for the treatment of herpesviral infections | IRF3, PML, TPMT | TTBK1 448/4885TTBK2 704/4885AURKA 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.